Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Moderna’s Product Revenue by region, split between the United States and the rest of the world, reported on a quarterly basis from Q1 2021 onwards.
Moderna’s major market for supplying their COVID-19 vaccine has been the United States. Gradually, they also began their international sales. WHO and other health agencies authorized the use of their vaccine in over fifty countries. In early 2021, the company declared that they would be supplying their vaccines to 92 low and middle-income countries in Q4 2021 through COVAX. They also received authorization for their COVID-19 vaccine for adolescent use in the European Union, countries like the United Kingdom, Japan, Switzerland, Canada, Saudi Arabia, Taiwan, Philippines, and Australia. For supplying this vaccine, they entered into supply agreements with not only the United States but also UNICEF and the African Union– agreeing to sell approximately 110 million vaccines to African countries in October, 2021.
Moderna’s Product Revenue by Region
|Revenue by region||Q1 2021||Q2 2021||Q3 2021|
|Rest of world||375||2,104||3,613|
(All figures are in millions)
Moderna’s Revenue Contribution by Region
|Revenue Contribution by region||Q1 2021||Q2 2021||Q3 2021|
|Rest of world||21.64%||50.13%||75.11%|
There is a gradual rise in the total revenue with every quarter. Q1 2021 recorded $1,733 million being the lowest of the three quarters. The latest quarter (Q3 2021) recorded the highest total of $4,810 million. Furthermore, the company earned $1,197 million sales revenue from the United States and $3,613 million from foreign sales — thereby amounting to a total of $4,810 million split into 24.89% and 75.11% between US and foreign sales respectively. What we can infer from this data is that Moderna’s product sales were mainly concentrated in the States. International sales were relatively slimmer with the company focusing on the US as its primary market.
In comparison to Q2 2021; Moderna’s total revenue increased from $4,197 to $4,810 in Q3 2021 marking a 14.61% growth on a quarter-on-quarter basis, owing to the surge in the sale of their product. The company delivered about 73 million doses of their COVID-19 vaccine in the United States along with around 136 million doses to international countries. Total revenue for 9 months till September 30, 2021, increased by $11 billion as compared to the same period of the previous year—this is because of the increase in product sales and grant revenue. For this period, Moderna delivered about 287 million doses to the United States and about 222 million doses to foreign governments.
About Moderna Inc.
Moderna, Inc. was incorporated in 2016 in Delaware. Working in the field of biotechnology, their work of new transformative medicine creation is based on messenger RNA that aims to improve patient lives. They operate in a reporting segment that largely focuses on the commercialization of mRNA medicines including its discovery and subsequent development. Their platform is structured to build on constant developments in mRNA science, manufacturing, and delivery technology. In 2020, they received authorization for their COVID-19 vaccine from the WHO and other health organizations and agencies in several countries. This is their only commercial product authorized for use.
Did you like Moderna’s Product Revenue by Region statistic?
Access thousands of more such key performance indicators, on thousands of listed companies, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.